Skip to content
MS
Sign in
Shared (2 pathways) Pathway metabolite unreviewed

Carbamoyl phosphate

0
Pathways
0
Categories
0
As substrate
0
As product
What can this become? Show on map

Reactions involving Carbamoyl phosphate

Every recorded step where this molecule takes part

All 4 Consumed 2 Produced 2

Showing all 4 reactions.

Pathway junctions through this molecule

Produced in one pathway, consumed in another

2 links
Produced in Consumed in Link
Pyrimidine De Novo Synthesis (through to UM… → Urea Cycle cross-category
Urea Cycle → Pyrimidine De Novo Synthesis (through to UM… cross-category

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Cordycepin suppresses growth and virulence of <i>Magnaporthe oryzae</i> via mitochondrial function and carbonic anhydrase-associated nitrogen metabolism.

    Dang Y, Li Y, Xu G, Wang T, An Q, Gao F, Liang X, Ji X, Li Q, Wang L. · 2026-04-22

    open access unreviewed
  2. 2
    Systematic metabolic engineering of <i>Escherichia coli</i> for high-level production of pseudouridine via pathway optimization and precursor enhancement.

    Song J, Shen W, Xia Y, Zhou L, Zhou Y, Yang H, Chen X. · 2026-04-06

    open access unreviewed
  3. 3
    Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy.

    Chen J, Wang Y, Xu L, Li X, Zhao L. · 2026-02-27

    open access unreviewed
  4. 4
    Gut microbial ammonia as a mediator of PFOS neurotoxicity and its remediation by the flavonoid Icaritin.

    Yi Y, Zhang W, Wei Y, Ran W, Liu D, Deng W, Duan S, Yao J, Wang L, Zhang Y, Gao J, Gong Q. · 2026-02-02

    cited 1× open access unreviewed
  5. 5
    Neurotransmitter receptor-associated gene signature: prognostic and immunosuppressive microenvironment in NSCLC.

    Yang Y, Ge A, Xu Y, Li J, Shi W, Wang J, Zhao Z. · 2026-01-06

    open access unreviewed
  6. 6
    CAD drives Angiotensin II-induced vascular smooth muscle cell activation via upregulation of pyrimidine biosynthesis and rRNA synthesis.

    Park MJ, Kim D, Park KG, Jeong GH, Byun JK, Choi YK. · 2026-06-09

    unreviewed
  7. 7
    De novo biosynthesis of putrescine from glucose using engineered <i>Escherichia coli</i> in a two-step process.

    Yin L, Li H, Du M, Liu Z, Wang J, Xu S, Wang X, Chen K. · 2026-03-04

    open access unreviewed
  8. 8
    In Vivo Base Editing for Neonatal Inborn Errors of Metabolism: Clinical Progress, N-of-1 Therapy, and the Ethics of Bespoke Genetic Medicine.

    Li OM, Li Y, Li SXT. · 2026-08-11

    unreviewed
  9. 9
    Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles.

    Ciganek I, Delehedde C, Galy A, Cogné M, Rameix N, Bordeianu C, Pichon C. · 2026-06-08

    open access unreviewed
  10. 10
    Urea cycle dysregulation and arginine pathways in the pathogenesis of NAFLD and NASH (Review).

    Zhu B, Wang C, Liu P, Qu Z, Qi R, Chen S, Niu H. · 2026-06-11

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.